News

Daily treatment with BCX7353, an investigative oral inhibitor of plasma kallikrein, reduces the rate of attacks in hereditary angioedema (HAE) patients by more than 70%, a Phase 2 study shows. Also, more patients receiving the prophylactic, or preventive, treatment remained without an attack during the study’s four-week duration. The study,…

Researchers have developed a new way to distinguish bradykinin-mediated angioedema from histamine-mediated angioedema. This biomarker tool may improve the use of targeted therapies in angioedema patients. The study, “Threshold‐Stimulated Kallikrein Activity Distinguishes Bradykinin‐ From Histamine‐Mediated Angioedema,” was published in Clinical & Experimental Allergy. Angioedema encompasses…

The U.S. Food and Drug Administration recently approved Shire’s Cinryze (C1 esterase inhibitor [human]) to help prevent angioedema attacks in children 6 and older who live with hereditary angioedema (HAE). Cinryze was first approved in the U.S. in 2008 for routine preventive treatment against attacks in…

A study that examined three forms of angioedema suggests there are different processes contributing to the development of each disease. Researchers found that patients with angioedema of unknown cause have significantly different clinical manifestations compared to patients with hereditary angioedema caused by a genetic deficiency in the C1-inhibitor protein. The…